Study on anti-inflammatory action of simvastatin in rats with chronic obstructive pulmonary disease and its mechanism

LIU Qing; SUN Bojian; REN Dongfei; LI Lin; YANG Zhihui; LIANG Ruikai

doi:10.7619/jcmp.20211138

Journal of Clinical Medicine in Practice > 2021 > 25(18): 15-19. > DOI: 10.7619/jcmp.20211138

LIU Qing, SUN Bojian, REN Dongfei, LI Lin, YANG Zhihui, LIANG Ruikai. Study on anti-inflammatory action of simvastatin in rats with chronic obstructive pulmonary disease and its mechanism[J]. Journal of Clinical Medicine in Practice, 2021, 25(18): 15-19. DOI: 10.7619/jcmp.20211138

Citation:

PDF (691 KB)

Study on anti-inflammatory action of simvastatin in rats with chronic obstructive pulmonary disease and its mechanism

1.
Department of Respiratory Medicine, the Eighth People's Hospital of Hebei Province, Shijiazhuang, Hebei, 050021
2.
Department of Rheumatology and Immunology, the First Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000

More Information

Received Date: March 16, 2021
Available Online: October 19, 2021
Published Date: September 27, 2021

Graphical Abstract

Abstract

Abstract

Objective     To study on anti-inflammatory action of simvastatin in rats with chronic obstructive pulmonary disease (COPD) and its mechanism.
Methods     A total of 50 male SD rats were given 7 d adaptive feeding, and 10 rats were randomly selected and taken as blank control group, and the remaining 40 rats were used to establish COPD model. After successful modeling, they were randomly divided into four groups[the model group, low-dose group, middle-dose group and high-dose group simvastatin], with 10 rats in each group. The bronchoalveolar lavage fluid of rats was collected, and the levels of inflammatory factors were detected. The expression of retinoic acid related orphan receptor ROR-γt mRNA was measured, and the pulmonary function was evaluated.
Results     The levels of pulmonary function indexes of rats in blank control group were the highest, and the rank of the rest four groups from high to low was as follows: high-dose group, middle-dose group, low-dose group and model group. There were no statistically significant differences in the levels of inflammatory factors and the relative expression of ROR-γt mRNA between the low-dose and medium-dose groups (P>0.05). There were statistically significant differences in the levels of inflammatory factors and the relative expression of ROR-γt mRNA among other groups (P < 0.05).
Conclusion     Simvastatin has an ideal anti-inflammatory effect for COPD rats, which may be related to the inhibition of ROR-γt expression by drugs, and the mechanism is that pulmonary function of rats can be improved by inhibiting inflammation.

FullText(HTML)

References (27)

References

[1]	VIGNOLI A, SANTINI G, TENORI L, et al. NMR-based metabolomics for the assessment of inhaled pharmacotherapy in chronic obstructive pulmonary disease patients[J]. J Proteome Res, 2020, 19(1): 64-74. doi: 10.1021/acs.jproteome.9b00345
[2]	WANG W, WANG P, LI Q, et al. Alterations of grey matter volumes and network-level functions in patients with stable chronic obstructive pulmonary disease[J]. Neurosci Lett, 2020, 720: 134748. doi: 10.1016/j.neulet.2020.134748
[3]	张晶, 栾晓嵘, 郝俊萍, 等. 慢性阻塞性肺疾病伴肺部感染者相关细胞因子的表达及其与肺功能的关系[J]. 中华医院感染学杂志, 2019, 29(13): 1954-1958. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY201913010.htm
[4]	LENÁRTOVÁP, KOPĈ EKOVÁJ, GAŽAROVÁM, et al. Biochemical parameters as monitoring markers of the inflammatory reaction by patients with chronic obstructive pulmonary disease (COPD)[J]. Rocz Panstw Zakł Hig, 2017, 68(2): 185-190. http://yadda.icm.edu.pl/yadda/element/bwmeta1.element.agro-c1ca410b-f7b8-4236-add3-e379061499ca/c/RPZH_2017_Vol_68_No_2_pp._185-190.pdf
[5]	王慧杰, 徐武成, 黄华琼. 慢性阻塞性肺疾病急性加重期炎性生物标志物研究进展[J]. 国际呼吸杂志, 2019, 39(2): 134-138. doi: 10.3760/cma.j.issn.1673-436X.2019.02.011
[6]	路明, 姚婉贞. 2019年版慢性阻塞性肺疾病全球创议主要更新内容解读(非药物治疗篇)[J]. 中华结核和呼吸杂志, 2019, 42(3): 238-240, 192.
[7]	SO J Y, DHUNGANA S, BEROS J J, et al. Statins in the treatment of COPD and asthma-where do we stand?[J]. Curr Opin Pharmacol, 2018, 40: 26-33. doi: 10.1016/j.coph.2018.01.001
[8]	SAKHAMURI S, CHATTU V K. Statins in COPD: selection modalities and mortalities[J]. Chest, 2018, 153(2): 578. http://www.sciencedirect.com/science?_ob=ShoppingCartURL&_method=add&_eid=1-s2.0-S0012369217332373&originContentFamily=serial&_origin=article&_ts=1517836099&md5=183e6fa9ad06b58a6c4467e580f141d2
[9]	芦永斌, 常锐霞, 姚佳, 等. 长期使用不同他汀类药物治疗COPD患者的meta分析[J]. 中国现代应用药学, 2019, 36(7): 846-854. https://www.cnki.com.cn/Article/CJFDTOTAL-XDYD201907016.htm
[10]	张迪, 夏艺, 范丽, 等. 慢性阻塞性肺疾病大鼠模型的建立与评价[J]. 中国实验动物学报, 2020, 28(2): 83-88. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGSD202002012.htm
[11]	高文祥, 高钰琪, 陈建, 等. 医学实验课中实验动物伦理学要求的实施与思考[J]. 中华医学教育探索杂志, 2013, 12(12): 1250-1252.
[12]	世界中医药学会联合会. 国际中医临床实践指南慢性阻塞性肺疾病[J]. 世界中医药, 2020, 15(7): 1084-1092. https://www.cnki.com.cn/Article/CJFDTOTAL-SJZA202007031.htm
[13]	DUNN B. Updated guidelines for chronic obstructive pulmonary disease[J]. JAAPA, 2019, 32(1): 49-51. doi: 10.1097/01.JAA.0000550297.68348.78
[14]	NAKAMOTO K, WATANABE M, SADA M, et al. Pseudomonas aeruginosa-derived flagellin stimulates IL-6 and IL-8 production in human bronchial epithelial cells: a potential mechanism for progression and exacerbation of COPD[J]. Exp Lung Res, 2019, 45(8): 255-266. doi: 10.1080/01902148.2019.1665147
[15]	KUBYSHEVA N, BOLDINA M, ELISEEVA T, et al. Relationship of serum levels of IL-17, IL-18, TNF-α, and lung function parameters in patients with COPD, asthma-COPD overlap, and bronchial asthma[J]. Mediat Inflamm, 2020, 2020: 4652898. http://www.researchgate.net/publication/342894294_Relationship_of_Serum_Levels_of_IL-17_IL-18_TNF-_a_and_Lung_Function_Parameters_in_Patients_with_COPD_Asthma-COPD_Overlap_and_Bronchial_Asthma/download
[16]	蔡东林, 孙钟和, 赵益庆. 慢性阻塞性肺疾病稳定期BODE指数、IL-8、TNF-α水平与肺肾气虚证相关性研究[J]. 陕西中医, 2020, 41(11): 1573-1575. doi: 10.3969/j.issn.1000-7369.2020.11.015
[17]	陈锋, 李群, 吴迪, 等. 哮喘-慢性阻塞性肺疾病重叠综合征患者呼出气冷凝集液中TNF-α、IL-8、IL-10的检测水平及意义[J]. 国际呼吸杂志, 2020, 40(8): 566-571. doi: 10.3760/cma.j.cn131368-20190620-00907
[18]	LI B, REN Q, LING J, et al. The change of Th17/Treg cells and IL-10/IL-17 in Chinese children with Henoch-Schonlein Purpura: a PRISMA-compliant meta-analysis[J]. Medicine: Baltimore, 2019, 98(3): e13991. doi: 10.1097/MD.0000000000013991
[19]	ROOS A B, MORI M, GURA H K, et al. Increased IL-17RA and IL-17RC in end-stage COPD and the contribution to mast cell secretion of FGF-2 and VEGF[J]. Respir Res, 2017, 18(1): 48. doi: 10.1186/s12931-017-0534-9
[20]	莫翠英, 关洁萍, 黄嘉艺, 等. IL-32与CCL-18在不同严重程度慢性阻塞性肺疾病患者中的表达水平分析[J]. 中国病案, 2019, 20(4): 98-101. doi: 10.3969/j.issn.1672-2566.2019.04.035
[21]	EURLINGS I M J, REYNAERT N L, VAN DE WETERING C, et al. Involvement of c-Jun N-terminal kinase in TNF-α-driven remodeling[J]. Am J Respir Cell Mol Biol, 2017, 56(3): 393-401. doi: 10.1165/rcmb.2015-0195OC
[22]	王戈. 阿托伐他汀对烟熏慢性阻塞性肺病大鼠肺组织内质网应激和炎症的影响[J]. 河北医药, 2019, 41(10): 1502-1505. doi: 10.3969/j.issn.1002-7386.2019.10.014
[23]	HU S Y, HSIEH M S, LIN T C, et al. Statins improve the long-term prognosis in patients who have survived Sepsis: a nationwide cohort study in Taiwan (STROBE complaint)[J]. Medicine, 2019, 98(17): e15253. doi: 10.1097/MD.0000000000015253
[24]	叶雪丹, 王君, 陆园园, 等. 辛伐他汀联合噻托溴铵治疗慢性阻塞性肺病合并肺动脉高压的临床研究[J]. 中国临床药理学杂志, 2019, 35(9): 8-10. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ201909002.htm
[25]	王燕, 黄旭晴, 徐长青, 等. 辛伐他汀联合阿奇霉素治疗老年慢性阻塞性肺疾病合并肺动脉高压患者的临床研究[J]. 中国临床药理学杂志, 2020, 36(17): 2606-2609. https://www.cnki.com.cn/Article/CJFDTOTAL-GLYZ202017003.htm
[26]	徐健强, 赵国军, 王燕, 等. 阿托伐他汀的抗炎作用及其机制的研究进展[J]. 中国动脉硬化杂志, 2016, 24(4): 419-423. https://www.cnki.com.cn/Article/CJFDTOTAL-KDYZ201604021.htm
[27]	孙焱, 陶芝伟, 康珏宁, 等. 阿托伐他汀对草酸钙晶体诱导的细胞炎症反应的影响及其机制探讨[J]. 中华泌尿外科杂志, 2019(10): 780-785. doi: 10.3760/cma.j.issn.1000-6702.2019.10.012

Cited By

Get Citation

PDF

XML

Article views (256) PDF downloads (17)

Turn off MathJax

Article Contents

Abstract

References

Study on anti-inflammatory action of simvastatin in rats with chronic obstructive pulmonary disease and its mechanism

Abstract

References

Catalog

Export File

Citation

Format

Content